跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
MENVEO SOLUCION INYECTABLE - CIMA-AEMPS Drug Approval Details
Approvals
/
CIMA-AEMPS
/
MENVEO SOLUCION INYECTABLE
Approved
STANDARD
MENVEO SOLUCION INYECTABLE
Glaxosmithkline Vaccines S.R.L.
🇪🇸 Spanish Agency of Medicines and Medical Devices
Approval Date
Nov 29, 2024
Approval ID
82abf20d08a1c641
Company
Glaxosmithkline Vaccines S.R.L.
Type
Standard
Approval Details
Approval Id
82abf20d08a1c641
Drug Cima Aemps Name
MENVEO SOLUCION INYECTABLE
Register Number
110614005
Holder Company Name
Glaxosmithkline Vaccines S.R.L.
Marketing Company Name
Glaxosmithkline S.A.
Marketing Company Detail Path
/organization/glaxosmithkline-sa
Authorization Date
2024-11-29
Dosage Form
SOLUCIÓN INYECTABLE
Dose
0,5 ml
Route Of Administration
VÍA INTRAMUSCULAR
Prescription Type
Medicamento Sujeto A Prescripción Médica
Commercialized
No
Company Name
Glaxosmithkline Vaccines S.R.L.
Company Information
Pharmaceutical Company Name
GLAXOSMITHKLINE SA
Country Name
Spain
City Name
tres cantos,madrid,country_es
Address
CALLE DE SEVERO OCHOA (- PQ TECNOLOGICO DE MADRID) 2
Active Ingredients
ANTIGENO OLIGOSACARIDO MENINGOCOCO GRUPO A
10 µg
ANTIGENO OLIGOSACARIDO MENINGOCOCO GRUPO C
5 µg
ANTIGENO OLIGOSACARIDO MENINGOCOCO GRUPO W135
5 µg
ANTIGENO OLIGOSACARIDO MENINGOCOCO GRUPO Y
5 µg
Approved
Quick Info
Agency
CIMA-AEMPS
Country
🇪🇸
Approval Date
Nov 29, 2024
Approval ID
82abf20d08a1c641
Type
Standard
Back to CIMA-AEMPS Approvals